Clinical Trials Logo

Dyskinesia, Drug-Induced clinical trials

View clinical trials related to Dyskinesia, Drug-Induced.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05148884 Completed - Clinical trials for Medication-Induced Dyskinesia

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.

NCT ID: NCT03354455 Completed - Parkinson Disease Clinical Trials

Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Using a within‐subject cross‐over design, we will include 20 patients with Parkinson disease (PD) and peak‐of‐dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication. On two separate days, each patient will receive off‐line, effective (high‐intensity) or ineffective (low‐intensity) 1 Hz repetitive transcranial magnetic stimulation (rTMS) of the presupplementary motor area (preSMA) before functional magnetic resonance (fMRI). Immediately after the patient will perform a Go/No-Go task during fMRI in the the OFF state for 9 minutes. Then the scan is paused and the patient will receive 200 mg fast‐acting oral levodopa and undergo whole‐brain task‐related fMRI at 3 Tesla until peak‐of‐dose dyskinesia will emerge. During task‐related fMRI, patients has to click on a mouse with their right hand (Right‐Go), left hand (Left‐Go), or no action (No‐Go) in response to arbitrary visual cues. The patients will also be tested for different aspects of impulsivity using neuropsychological questionnaires and computerized tests.

NCT ID: NCT02657681 Completed - Parkinson's Disease Clinical Trials

Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's disease. Half of the patients will receive real tSMS treatment, the other half will receive sham treatment (placebo).

NCT ID: NCT01173731 Completed - Parkinson Disease Clinical Trials

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced dyskinesias).

NCT ID: NCT00255879 Completed - Clinical trials for Dyskinesia, Drug-Induced

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Start date: January 1999
Phase: Phase 1
Study type: Interventional

This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.

NCT ID: NCT00175955 Completed - Clinical trials for Dyskinesia, Medication-induced

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Start date: May 2005
Phase: Phase 2
Study type: Interventional

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia